ESMO When 2 experts meet | Colorectaal Carcinoom

Tijdens het ESMO-congres in Barcelona gaan dr. Jeanine Roodhart van het UMC Utrecht en dr. Liselot Valkenburg-van Iersel van het Maastricht UMC+ met elkaar in gesprek over het nieuws dat werd gepresenteerd op het gebied van colorectaal carcinoom. In het tweegesprek worden alle belangrijke studies over neo-adjuvante immuuntherapie, nieuwe behandelopties met immuuntherapie en rectumsparende strategieën besproken

Aan bod komen de volgende studies:

• POD1UM-303/InterAACT 2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy (Chemo)
•  Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
• Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study
• IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort
• Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial
• Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial
• Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial
• Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study
• Encorafenib + Cetuximab (EC) + FOLFIRI for BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC): Updated Results From the BREAKWATER Safety Lead-In (SLI)
• Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study

Bekijk hier de andere programma's van ESMO.

Dit programma komt onafhankelijk tot stand en wordt financieel mogelijk gemaakt door AstraZeneca, MSD, Pierre Fabre en Roche.